The Department of Veterans Affairs (VA) National Acquisition Center awarded an Indefinite Delivery Contract to Avkare, LLC, a for-profit limited liability company, to provide Oxybutynin extended-release (ER) tablets. The single-award contract has a potential value of $24,778,012.45 and covers a base year with four one-year option periods, expiring on May 8, 2025.
The contract aims to establish a reliable source of supply for Oxybutynin ER tablets in various package sizes to support the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The pre-solicitation notice indicates the contract items will be distributed through the VA's and DoD's respective Pharmaceutical Prime Vendor Programs. Avkare, as an experienced federal contractor, provides a range of pharmaceutical and medical products to government agencies, including previous contracts with the Defense Logistics Agency and VA to supply various drugs and medical equipment.
Generated 4/10/24, 9:17 AM